Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2019 07:30 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019

The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen. Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to...
March 25, 2019 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

--On Track to Complete its Three Phase 3 Clinical Trials in 2019----Received Qualified Infectious Disease Product Designation in Four Additional Indications----Fast Track Designation received from...
March 19, 2019 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

DUBLIN, Ireland and CHICAGO, March 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
February 19, 2019 07:30 ET | Source: Iterum Therapeutics plc

Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
November 14, 2018 07:15 ET | Source: Iterum Therapeutics plc

Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights

DUBLIN, Ireland and CHICAGO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
November 05, 2018 16:05 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc to Participate in Investor Conferences in November and December

DUBLIN, Ireland and CHICAGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
October 05, 2018 08:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018

DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
September 25, 2018 16:05 ET | Source: Iterum Therapeutics plc

Iterum to Present at Cantor Fitzgerald Global Healthcare Conference

DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
September 20, 2018 08:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018

DUBLIN, Ireland and CHICAGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
September 18, 2018 08:00 ET | Source: Iterum Therapeutics plc

Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections

Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...